On Friday, Navistar International Corp (NYSE:NAV)’s shares inclined 0.06% to $17.54.
International Truck declared James Wright as the recipient of the Diamond Renewed™ Used Truck Giveaway promoted during this year’s Mid-America Trucking Show. The promotion drove traffic to the International Used Truck booth and raised awareness of Diamond Renewed, the industry’s most comprehensive certified used truck program.
Wright received his 2012 International® ProStar® tractor at the company’s Nashville Used Truck Center. The International ProStar is equipped with a MaxxForce® 13 engine and a 9-speed manual Eaton® Fuller® transmission.
The Diamond Renewed program puts used International trucks through the industry’s most comprehensive inspection and mechanical reconditioning process. Technicians review more than 180 checkpoints and conduct mechanical and aesthetic reconditioning counting cleaning or replacing diesel particulate filters (DPF) and diesel oxidation catalysts (DOC), exhaust gas recirculation (EGR) calibration software updates, checking and repairing brake systems, conducting major body repair, painting the frame rail and more. Vehicles also come standard with the industry leading System1™ confidence warranty, in addition to the OnCommand™ Connection remote diagnostics system, and Repair Advocate.
Navistar International Corporation manufactures and sells commercial and military trucks, diesel engines, and school and commercial buses; and provides service parts for trucks and diesel engines worldwide. It operates through four segments: North America Truck, North America Parts, Global Operations, and Financial Services.
CTI BioPharma Corp (NASDAQ:CTIC)’s shares gained 0.27% to $1.85.
CTI BioPharma Corp. (CTIC) declared findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). These final results were presented by Dr. Giuseppe Visani, Director of Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy in a poster session (abstract #P564) during the 20th Congress of the European Hematology Association (EHA), June 11-14, 2015 in Vienna, Austria.
AML is the most common acute leukemia affecting adults, and its incidence enhances with age. AML may develop from the progression of other diseases, such as MDS, which is a blood cancer that also affects the bone marrow and leads to a decrease in circulating red blood cells. Tosedostat is a potential first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, counting non-small cell lung, ovarian, breast, and prostate cancers.
At the end of Friday’s trade, TransCanada Corporation (USA) (NYSE:TRP)‘s shares surged 0.57% to $38.91.
TransCanada Corporation (TRP) declared that the Board of Directors (Board) of TransCanada declared a quarterly dividend of $0.52 per common share for the quarter ending September 30, 2015, on the Company’s outstanding common shares. The common share dividend is payable on October 30, 2015, to shareholders of record at the close of September 30, 2015.
TransCanada Corporation operates as an energy infrastructure company in North America. The company operates in three segments: Natural Gas Pipelines, Liquids Pipelines, and Energy. The Natural Gas Pipelines segment owns and operates natural gas pipelines and regulated natural gas storage facilities.
Firstmerit Corp (NASDAQ:FMER), ended its Friday’s trading session with 0.43% gain, and closed at $18.74.
FirstMerit Corporation (FMER) signed a Planned Partnership agreement with The U.S. Department of Commerce – International Trade Administration. As a Planned Partner, FirstMerit will support the International Trade Administration’s mission of broadening and deepening the U.S. exporter base.
FirstMerit Corporation operates as the bank holding company for FirstMerit Bank N.A. that provides various banking, fiduciary, financial, insurance, and investment services to corporate, institutional, and individual customers. The company’s Commercial segment offers commercial term loans, revolving credit arrangements, asset-based lending, leasing, commercial mortgages, real estate construction lending, and letters of credit, in addition to treasury administration, government banking, international banking, merchant card, and other depository products and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
